TODO: Skip to main content
Top
Gepubliceerd in:

26-08-2020 | Original Research

The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data

Auteurs: Ali Vedadi, Sharara Shakik, M. Catherine Brown, Benjamin H. Lok, Frances A. Shepherd, Natasha B. Leighl, Adrian Sacher, Penelope A. Bradbury, Wei Xu, Geoffrey Liu, Grainne M. O’Kane

Gepubliceerd in: Quality of Life Research | Uitgave 2/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Small cell lung cancer (SCLC) is a highly fatal disease associated with significant morbidity, with a need for real-world symptom and health utility score (HUS) data. HUS can be measured using an EQ-5D-5L questionnaire, however most captured data is available in non-SCLC (NSCLC) only. As new treatment regimens become available in SCLC it becomes important to understand factors which influence health-related quality of life and health utility.

Methods

A prospective observational cohort study (2012–2017) of ambulatory histologically confirmed SCLC evaluated patient-reported EQ-5D-5L-derived HUS, toxicity and symptoms. A set of NSCLC patients was used to compare differential factors affecting HUS. Clinical and demographic factors were evaluated for differential interactions between lung cancer types. Comorbidity scores were documented for each patient.

Results

In 75 SCLC and 150 NSCLC patients, those with SCLC had lower mean HUS ((SCLC vs NSCLC: mean 0.69 vs 0.79); (p < 0.001)) when clinically stable and with progressive disease: ((SCLC mean HUS = 0.60 vs NSCLC mean HUS = 0.77), (p = 0.04)). SCLC patients also had higher comorbidity scores ((1.11 vs 0.73); (p < 0.015)). In multivariable analyses, increased symptom severity and comorbidity scores decreased HUS in both SCLC and NSCLC (p < 0.001); however, only comorbidity scores differentially affected HUS (p < 0.0001), with a greater reduction of HUS adjusted per unit of comorbidity in SCLC.

Conclusion

Patients with advanced SCLC had significantly lower HUS than NSCLC. Both patient cohorts are impacted by symptoms and comorbidity, however, comorbidity had a greater negative effect in SCLC patients.
Bijlagen
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Literatuur
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Metagegevens
Titel
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data
Auteurs
Ali Vedadi
Sharara Shakik
M. Catherine Brown
Benjamin H. Lok
Frances A. Shepherd
Natasha B. Leighl
Adrian Sacher
Penelope A. Bradbury
Wei Xu
Geoffrey Liu
Grainne M. O’Kane
Publicatiedatum
26-08-2020
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-020-02615-1